The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ONL Therapeutics Secures $65 Million in Series D Financing Led by Johnson & Johnson Innovation
Sep 13, 2024•almost 2 years ago
Contract Type
partnership
Ann ArborBiotechnologyHealth CareBiopharma
Description
ONL Therapeutics, Inc. has secured $65M in Series D financing led by Johnson & Johnson Innovation – JJDC, Inc. The funding will enable the company to advance the clinical development program for ONL1204, a novel therapy for protecting the vision of patients with retinal disease.
Company Information
Company
ONL Therapeutics
Location
524 S. Main St
Ann Arbor, Michigan, United States
About
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision.
Ann ArborBiotechnologyHealth CareBiopharma